Grant: Discovery Grants Program - Individual
University of Western Ontario
$22,000.00
Multimodal Metabolic Imaging with Hybrid Positron Emission Tomography and Magnetic Resonance Imaging (PET/MRI) Systems
EF 2016-17
Résumé
Modern imaging technologies such as magnetic resonance imaging (MRI) and positron emission tomography (PET) allow us to image, non-invasively, the inner workings of the body. PET creates three-dimensional images of radio-labelled, biologically active molecules that have been injected in a patient. The most commonly used PET tracer is a glucose analogue labelled with radioactive fluorine (FDG), which can be used to locate metabolically active regions, such as cancer cells or inflammation. FDG-PET is limited, however, to certain patients and studies due to limited resolution and additional radiation dose. An alternative method for imaging metabolism has been proposed using MRI. It relies on the chemical exchange between protons in metabolites such as glucose and the protons in water that comprise most of the MRI signal. Using MRI methods such as chemical exchange saturation transfer (CEST) and chemical exchange-sensitive spin lock (CESL) imaging, we can measure the change of signal due to chemical exchange and relate it to the concentration of different metabolites, such as glucose, creatine, and glutamate. If comparable to FDG-PET, this would allow the MRI to acquire metabolic images in patients that normally can't be exposed to radioactive tracers, such as pregnant women or young children. MRI can also acquire images with much higher resolution than PET, potentially probing the heterogeneity of metabolic signals.
Hybrid PET/MRI systems such as the Siemens Biograph mMR combine the sensitivity and specificity of PET with the anatomical, structural and functional capabilities of MRI, enabling new research into novel PET probes and multimodal imaging methods. In order to measure different metabolic and neurotransmitter processes simultaneously with PET/MRI, my lab is developing MRI methods sensitive to chemical exchange (CE) on hybrid PET/MRI systems. CE-MRI is capable of imaging metabolites such as glucose, creatine, or glutamate, at millimolar concentrations whereas PET is capable of detecting tracers with up to a billion-fold increase in sensitivity, but is limited to one PET probe of interest at a time. Measuring metabolic activity with CE-MRI would free the PET system to image low concentration, disease-specific PET probes, yielding simultaneous functional information that would be impossible to achieve with either imaging technology on its own. We believe that this could be one of the ""killer applications"" for PET/MRI.
In order to test new probes and develop new simultaneous PET/MRI methods, an MR-compatible PET insert is needed for simultaneous preclinical PET/MRI. Preclinical PET/MRI will play a key role in testing simultaneous CE-MRI and PET methods and translating them to human studies on the Biograph mMR. As a second research stream, I am developing methods and applications for a preclinical PET/MRI system that will complement the capabilities of our 3T PET/MRI.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
RGPIN-2015-05735
Name nom
Thiessen, Jonathan
Department département
Medical Biophysics - Medical Biophysics
Organization id
36
Institution établissement
University of Western Ontario
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2015
Award amount
22000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
1505
Committee name en
Physics
Committee name fr
Physique
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
3114
Research subject group en
Physics
Research subject group fr
Physique
Research subject en
Biological and Medical Physics
Research subject fr
Physique biologique et médicale
Partie
2
Nb partie
5
Application title
Multimodal Metabolic Imaging with Hybrid Positron Emission Tomography and Magnetic Resonance Imaging (PET/MRI) Systems
Keyword
NSERC
Application summary
Modern imaging technologies such as magnetic resonance imaging (MRI) and positron emission tomography (PET) allow us to image, non-invasively, the inner workings of the body. PET creates three-dimensional images of radio-labelled, biologically active molecules that have been injected in a patient. The most commonly used PET tracer is a glucose analogue labelled with radioactive fluorine (FDG), which can be used to locate metabolically active regions, such as cancer cells or inflammation. FDG-PET is limited, however, to certain patients and studies due to limited resolution and additional radiation dose. An alternative method for imaging metabolism has been proposed using MRI. It relies on the chemical exchange between protons in metabolites such as glucose and the protons in water that comprise most of the MRI signal. Using MRI methods such as chemical exchange saturation transfer (CEST) and chemical exchange-sensitive spin lock (CESL) imaging, we can measure the change of signal due to chemical exchange and relate it to the concentration of different metabolites, such as glucose, creatine, and glutamate. If comparable to FDG-PET, this would allow the MRI to acquire metabolic images in patients that normally can't be exposed to radioactive tracers, such as pregnant women or young children. MRI can also acquire images with much higher resolution than PET, potentially probing the heterogeneity of metabolic signals.
Hybrid PET/MRI systems such as the Siemens Biograph mMR combine the sensitivity and specificity of PET with the anatomical, structural and functional capabilities of MRI, enabling new research into novel PET probes and multimodal imaging methods. In order to measure different metabolic and neurotransmitter processes simultaneously with PET/MRI, my lab is developing MRI methods sensitive to chemical exchange (CE) on hybrid PET/MRI systems. CE-MRI is capable of imaging metabolites such as glucose, creatine, or glutamate, at millimolar concentrations whereas PET is capable of detecting tracers with up to a billion-fold increase in sensitivity, but is limited to one PET probe of interest at a time. Measuring metabolic activity with CE-MRI would free the PET system to image low concentration, disease-specific PET probes, yielding simultaneous functional information that would be impossible to achieve with either imaging technology on its own. We believe that this could be one of the ""killer applications"" for PET/MRI.
In order to test new probes and develop new simultaneous PET/MRI methods, an MR-compatible PET insert is needed for simultaneous preclinical PET/MRI. Preclinical PET/MRI will play a key role in testing simultaneous CE-MRI and PET methods and translating them to human studies on the Biograph mMR. As a second research stream, I am developing methods and applications for a preclinical PET/MRI system that will complement the capabilities of our 3T PET/MRI.